Sleeping Beauty‐based gene therapy with indoleamine 2,3‐dioxygenase inhibits lung allograft fibrosis

Sleeping Beauty (SB) transposon is a natural nonviral gene transfer system that can mediate long‐term transgene expression. Its potential utility in treating organ transplantation‐associated long‐term complications has not yet been explored. In the present study we generated an improved SB transposon encoding the human gene indoleamine‐2,3‐dioxygenase (hIDO), an enzyme that possesses both T cell‐suppressive and antioxidant properties and selectively delivered the SB transposon in combination with a hyperactive transposase plasmid to donor lung using the cationic polymer polyethylenimine (PEI) as transfection reagent. This nonviral gene therapeutic approach led to persistent and uniform transgene expression in the rat lung tissue without noticeable toxicity and inflammation. Importantly, IDO activity produced by hIDO transgene showed a remarkable therapeutic response, as evident by near normal pulmonary function (peak airway pressure and oxygenation), histological appearance, and reduced collagen content in lung allografts. In addition, we established a hIDO‐overexpressing type II cell line using the SB‐based gene transfer system and found that hIDO‐overexpressing lung cells effectively inhibited transforming growth factor–stimulated fibroblast proliferation in vitro. In summary, the SB‐based gene therapy with hIDO represents a new strategy for treating lung transplantation‐associated chronic complications, e.g., obliterative bronchiolitis.—Liu, H., Liu, L., Fletcher, B. S., Visner, G. A. Sleeping Beauty‐based gene therapy with indoleamine 2,3‐dioxygenase inhibits lung allograft fibrosis. FASEB J. 20, E1694 –E1703 (2006)

[1]  O. Hayaishi,et al.  Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Briegel,et al.  Bronchiolitis obliterans syndrome after (heart-)lung transplantation. Impaired antiprotease defense and increased oxidant activity. , 1999, American journal of respiratory and critical care medicine.

[3]  C. Densmore,et al.  Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  K. McDowell,et al.  Pathophysiology of asthma. , 2000, Respiratory care clinics of North America.

[5]  M. Vogeser,et al.  Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. , 2004, American journal of respiratory and critical care medicine.

[6]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[7]  A. J. Chandrasekhar,et al.  Analysis of risk factors for the development of bronchiolitis obliterans syndrome. , 1999, American journal of respiratory and critical care medicine.

[8]  D. Voytas,et al.  Controlling integration specificity of a yeast retrotransposon , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Michael Platten,et al.  Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite , 2005, Science.

[10]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[11]  J. Moffett,et al.  Tryptophan and the immune response , 2003, Immunology and cell biology.

[12]  M. Estenne,et al.  Bronchiolitis obliterans after human lung transplantation. , 2002, American journal of respiratory and critical care medicine.

[13]  F. Martinez,et al.  Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. , 1996, Journal of immunology.

[14]  Stefan Fischer,et al.  Impact of human interleukin-10 on vector-induced inflammation and early graft function in rat lung transplantation. , 2003, American journal of respiratory cell and molecular biology.

[15]  P. Hasleton,et al.  Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. , 1999, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[16]  K. Schechtman,et al.  Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. , 2004, American journal of respiratory and critical care medicine.

[17]  T. Egan,et al.  Lung transplantation: opportunities for research and clinical advancement. , 2005, American journal of respiratory and critical care medicine.

[18]  B. Reichart,et al.  Human Herpesvirus 6 in Bronchalveolar Lavage Fluid after Lung Transplantation: A Risk Factor for Bronchiolitis Obliterans Syndrome? , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[19]  S. Simões,et al.  Cationic liposomes for gene delivery: from biophysics to biological applications. , 2003, Current medicinal chemistry.

[20]  E. Kleinerman,et al.  Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  D. Largaespada,et al.  Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. , 2005, Blood.

[22]  P. Hopkins,et al.  Association of minimal rejection in lung transplant recipients with obliterative bronchiolitis. , 2004, American journal of respiratory and critical care medicine.

[23]  G. Visner,et al.  Pirfenidone Inhibits Lung Allograft Fibrosis through L‐Arginine–Arginase Pathway , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  E. Trulock,et al.  Minimal Acute Rejection after Lung Transplantation: A Risk for Bronchiolitis Obliterans Syndrome , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  F. Kelly,et al.  Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. , 1998, The European respiratory journal.

[26]  E. Raz,et al.  Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. , 2004, The Journal of clinical investigation.

[27]  Theresa A. Storm,et al.  AAV serotype 2 vectors preferentially integrate into active genes in mice , 2003, Nature Genetics.

[28]  J. Briegel,et al.  Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. , 2000, Transplantation.

[29]  K. Swanson,et al.  CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. , 2004, American journal of respiratory cell and molecular biology.

[30]  K. Sugimachi,et al.  Airway-directed gene transfer of interleukin-10 using recombinant Sendai virus effectively prevents post-transplant fibrous airway obliteration in mice , 2003, Gene Therapy.

[31]  W. Seeger,et al.  Reversal of experimental pulmonary hypertension by PDGF inhibition. , 2005, The Journal of clinical investigation.

[32]  C. Mah,et al.  Sustained FVIII expression and phenotypic correction of hemophilia A in neonatal mice using an endothelial-targeted sleeping beauty transposon. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[33]  Zoltán Ivics,et al.  Sleeping beauty transposition: biology and applications for molecular therapy. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[34]  L. Notterpek,et al.  Endothelial targeting of the Sleeping Beauty transposon within lung. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  Shawn M. Burgess,et al.  High-Resolution Genome-Wide Mapping of Transposon Integration in Mammals , 2005, Molecular and Cellular Biology.

[36]  G. Visner,et al.  Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury. , 2006, American journal of respiratory and critical care medicine.

[37]  B. Fletcher,et al.  Hyperactive transposase mutants of the Sleeping Beauty transposon. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.